Guzzo, Peter R. et al. published their patent in 2011 |CAS: 386704-04-7

The Article related to azabicycloalkane indole derivative preparation mch1 receptor antagonist treatment disease, Heterocyclic Compounds (More Than One Hetero Atom): Fused-Ring Systems With Two Or More Hetero Atoms, No More Than One Hetero Atom Per Ring and other aspects.Product Details of 386704-04-7

On January 6, 2011, Guzzo, Peter R.; Surman, Matthew David; Henderson, Alan John; Hadden, Mark; Freeman, Emily Elizabeth published a patent.Product Details of 386704-04-7 The title of the patent was Preparation of (azabicycloalkyl)indole and (azabicycloalkyl)pyrrolopyridine derivatives as MCH-1 receptor antagonists and use in the treatment of diseases. And the patent contained the following:

Title compounds I [R1 = H, (un)substituted alkyl, cycloalkyl, heteroaryl, etc; D = NR2; R2 = H, (un)substituted alkyl, alkynyl, aryl, etc.; each R3 independently = H, halo, NH2 and derivatives, (un)substituted heteroaryl, etc; R4 = H, halo, NH2 and derivatives, (un)substituted alkyl, aryl, etc; A = (CH)n; B = (un)substituted aryl, heteroaryl, cycloalkyl, etc.; L = (CH2)pO, (CH2)p, CH=CH, or bond; X = CR10, C(R10)2, N, or NR10; Y = CR10, C, or N; Z = CH, C, or N; R10 = H, halo, (un)substituted alkyl, cycloalkyl, heteroaryl, etc; m = 0 to 3; n = 1 or 2; p = 1 to 4; dash bond represents an optional double bound], and their pharmaceutically acceptable salts, oxides, solvates, or prodrugs, are prepared and disclosed as MCH-1 receptor antagonists and useful in the treatment of obesity, anxiety, depression, non-alc. fatty liver disease, and psychiatric disorders. Thus, e.g., II·2HCl was prepared by cross-coupling of 2-bromo-2-trifluoromethylpyridine with 2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine followed by demethylation, arylation with tert-Bu 3-bromo-5-methyl-5,6,7,8,9,10-hexahydro-7,10-iminocyclohept[b]indole-11-carboxylate, hydrolysis, and addition of hydrochloric acid. Select I were evaluated for their MCH-1 antagonistic activity, e.g., II·2HCl demonstrated a Ki value of 6.5 nM. The experimental process involved the reaction of (6-(Trifluoromethyl)pyridin-3-yl)methanol(cas: 386704-04-7).Product Details of 386704-04-7

The Article related to azabicycloalkane indole derivative preparation mch1 receptor antagonist treatment disease, Heterocyclic Compounds (More Than One Hetero Atom): Fused-Ring Systems With Two Or More Hetero Atoms, No More Than One Hetero Atom Per Ring and other aspects.Product Details of 386704-04-7

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts